Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a tablet for oral use. It is used for medical termination of intrauterine pregnancy up to 10 weeks gestation and for management of early pregnancy loss.

GNH USA supplies Mifegyne as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifegyne (mifepristone) is an antiprogestogen used in early pregnancy management.

Medical termination of intrauterine pregnancy (≤10 weeks gestation): induces decidual breakdown and facilitates expulsion of the gestational sac. Early pregnancy loss (≤10 weeks gestation): promotes evacuation of retained products of conception.

Mifegyne may cause a range of adverse reactions, most of which are mild and self‑limiting.

Common Side Effects: - Nausea or vomiting - Abdominal cramping or pain - Vaginal bleeding or spotting - Diarrhea - Headache - Fatigue

Serious or Rare Side Effects: - Heavy or prolonged bleeding requiring medical intervention - Severe infection (sepsis) after incomplete evacuation - Allergic reaction or anaphylaxis - Liver enzyme elevation or hepatic dysfunction - Uterine rupture (extremely rare)

Before prescribing Mifegyne, clinicians should consider several safety measures. - Confirm gestational age: ensure pregnancy is ≤10 weeks. - Verify diagnosis: rule out ectopic pregnancy. - Review medical history: avoid in patients with chronic adrenal failure or anticoagulant therapy. - Monitor bleeding: watch for excessive hemorrhage after administration. - Assess for contraindications: such as severe anemia or severe cardiovascular disease. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mifegyne can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce mifepristone effectiveness. - Concurrent prostaglandin analogues: can increase risk of uterine hyperstimulation. - Anticoagulants (e.g., warfarin): may amplify bleeding risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may raise mifepristone plasma levels. - NSAIDs: could mask abdominal pain, complicating assessment. - Hormonal contraceptives: effectiveness may be reduced, requiring alternative contraception.